Journal
NANOMEDICINE
Volume 5, Issue 7, Pages 1025-1036Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.10.97
Keywords
biodistribution; cancer; drug delivery; oral squamous cell carcinoma; PMPC; polymer; polymersome; tumor-associated macrophages
Funding
- Biocompatibles UK Ltd
- Royal Society Wolfson Research Merit Award
- Yorkshire Cancer Research
- ESPRC/White Rose DTC PhD studentship
- DTA EPSRC PhD studentship
- European Framework VI programme
Ask authors/readers for more resources
The prognosis for oral squamous cell carcinoma (OSCC) is not improving despite advances in surgical treatment. As with many cancers, there is a need to deliver therapeutic agents with greater efficiency into OSCC to improve treatment and patient outcome. The development of polymersomes offers a novel way to deliver therapy directly into tumor cells. Here we examined the internalization and biodistribution of two different fluorescently labeled polymersome formulations; polyethylene oxide (PEO)-poly 2-(diisopropylamino)ethyl methacrylate (PDPA) and poly 2-(methacryloyloxy)ethyl phosphorylcholine (PMPC)-PDPA, into SCC4 OSCC cells in vitro and in vivo. In vitro SCC4 monolayers internalized PMPC-PDPA and PEO-PDPA at similar rates. However, in vivo PMPC-PDPA polymersomes penetrated deeper and were more widely dispersed in SCC4 tumors than PEO-PDPA polymersomes. In the liver and spleen PMPC-PDPA mainly accumulated in tissue macrophages. However, in tumors PMPC-PDPA was found extensively in the nucleus and cytoplasm of tumor cells as well as in tumor-associated macrophages. Use of PMPC-PDPA polymersomes may enhance polymersome-mediated antitumor therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available